Second Novartis Trial Conductor In Japan Reports Data Manipulation
This article was originally published in PharmAsia News
Executive Summary
A second Japan university has reported manipulation of data involved in clinical trials of a Novartis Pharma blood pressure drug, leading to a retraction of a published study of favorable results from the tests.